Isosorbide Mononitrate

Introduction Overview

Generic Name

isosorbide mononitrate

Brand Name

Imdur, Monoket, ISMO

Dosage Form

Extended-release tablets, Immediate-release tablets

Drug Class

Antianginal agents

Pharmacokinetics

Absorption:
Isosorbide mononitrate exhibits rapid and complete absorption after oral administration. The drug is highly bioavailable due to minimal first-pass hepatic metabolism, with an absolute bioavailability approaching 100%. Extended-release formulations are designed to maintain stable plasma concentrations over prolonged periods, optimizing therapeutic efficacy and minimizing nitrate tolerance. Absorption can be influenced by gastric pH and motility; however, food intake does not significantly impact bioavailability. Studies show peak plasma concentrations are typically reached within 1 to 2 hours with immediate-release forms, whereas extended-release tablets provide a gradual absorption ensuring sustained therapeutic levels.

Distribution:
Once absorbed, isosorbide mononitrate is widely distributed in body tissues, including cardiac muscle, vascular smooth muscle, and other organs. The drug exhibits a moderate volume of distribution, indicating tissue uptake beyond plasma. Plasma protein binding is low to moderate, generally under 20%, which facilitates free diffusion to target vascular tissues. There is limited binding to erythrocytes. Isosorbide mononitrate crosses the placenta and is detectable in breast milk, although clinical relevance requires further study.

Metabolism:
Isosorbide mononitrate undergoes minimal metabolism, primarily via hepatic pathways. It is not extensively metabolized by cytochrome P450 enzymes but undergoes denitration and other minor metabolic pathways to form inactive metabolites. The minimal hepatic metabolism underlies its high oral bioavailability. There is no significant induction or inhibition of metabolic enzymes reported, which reduces the likelihood of metabolic drug interactions.

Elimination:
The drug is eliminated mainly through renal excretion, with approximately 60% to 70% of the dose excreted unchanged in urine. The elimination half-life ranges from 5 to 6 hours for immediate-release preparations and can be prolonged with extended-release formulations. Clearance can be affected by renal function; therefore, dosing adjustments may be warranted in patients with renal impairment. There is no evidence of significant enterohepatic recycling. Steady-state plasma concentrations are achieved within 1 to 3 days of regular dosing.

Dosage Forms

Available Dosage Forms:
- Extended-release tablets available in 10 mg, 20 mg, 30 mg, 40 mg strengths.
- Immediate-release tablets available in 20 mg, 30 mg strengths.

Dosages for Adults and Adolescents:
- Initial dosing typically begins with 20 mg extended-release tablets once daily taken in the morning. Dose may be titrated upward based on clinical response and tolerability, with recommended doses ranging from 30 mg to 60 mg daily.
- For angina prophylaxis, 30 mg to 60 mg per day administered in one or two divided doses is common.
- Immediate-release tablets are less frequently used due to the need for multiple doses per day and higher potential for tolerance development.

Specific Patient Populations:
- In elderly patients, dosing should start at the lower effective dose with cautious titration due to higher sensitivity to hypotensive effects.
- In patients with renal impairment, dose adjustments are recommended, especially in severe renal dysfunction, due to decreased clearance.
- The safety and efficacy in pediatric populations have not been established.

Clinical Guidelines:
- Extended-release formulations are preferred for chronic management of angina to provide consistent plasma levels.
- Patients are advised to take tablets whole without crushing or chewing to maintain controlled release characteristics.
- Regular dosing adherence is critical to prevent angina attacks and avoid nitrate tolerance through proper dosing interval planning.

Mechanism Of Action

Isosorbide mononitrate acts primarily as a vasodilator through its biotransformation to nitric oxide (NO), a potent endogenous vasodilator. Upon enzymatic conversion in vascular smooth muscle cells, NO activates guanylate cyclase, increasing intracellular cyclic guanosine monophosphate (cGMP) levels. Elevated cGMP leads to dephosphorylation of myosin light chains, resulting in relaxation of vascular smooth muscle fibers. This vascular relaxation predominantly affects the venous capacitance vessels, decreasing venous return (preload), and to a lesser extent, systemic arterial resistance (afterload).

By reducing preload, isosorbide mononitrate decreases myocardial oxygen demand by lowering left ventricular end-diastolic pressure and volume. This effect alleviates the ischemic burden on the myocardium in patients with angina pectoris. Additionally, it improves coronary blood flow by dilating epicardial coronary arteries and collateral vessels, enhancing oxygen delivery to ischemic myocardial tissues.

Cellular pathways targeted by isosorbide mononitrate include stimulation of soluble guanylate cyclase in smooth muscle cells and inhibition of calcium influx through voltage-dependent channels, contributing to vasodilation. The nitrate group in isosorbide mononitrate is essential for its conversion to NO, distinguishing it from other vasodilators acting via different mechanisms such as calcium channel blockers or beta-blockers.

Compared to other nitrates such as nitroglycerin, isosorbide mononitrate has a longer half-life and more consistent bioavailability, allowing for once or twice daily dosing. This pharmacokinetic profile makes it favorable for prophylactic therapy rather than acute angina relief. Clinical studies consistently show its efficacy in reducing angina frequency and improving exercise tolerance due to sustained vasodilatory effects, which are underpinned by its molecular mechanism.

Pharmacological Actions

Vasodilation of systemic veins and arteries through nitric oxide-mediated smooth muscle relaxation.
Reduction of myocardial oxygen demand via decreased preload and afterload.
Coronary artery dilation enhancing oxygen supply to ischemic myocardium.
Inhibition of platelet aggregation via cGMP-mediated pathways.
Improvement of collateral coronary circulation in chronic ischemic heart disease.
Anti-anginal effect by balancing myocardial oxygen supply and demand.
Rapid absorption and high bioavailability ensuring effective systemic vasodilation.
Long half-life supporting sustained therapeutic plasma concentrations in extended-release formulations.
Minimization of nitrate tolerance when used with appropriate dosing intervals.
Lack of significant central nervous system penetration reducing sedative side effects.
Low potential for pharmacokinetic drug interactions due to minimal metabolism.
Positive hemodynamic effects in congestive heart failure through reduction of cardiac preload.
Ability to enhance exercise tolerance in patients with stable angina pectoris.
Reduction of pulmonary arterial pressure, beneficial in select pulmonary hypertension cases.

Therapeutic Or Clinical Uses

Prophylactic treatment of angina pectoris to reduce frequency and severity of chest pain episodes.
Chronic management of ischemic heart disease by improving myocardial oxygen balance.
Adjunctive therapy in congestive heart failure to decrease cardiac preload.
Alternative nitrate agent for patients intolerant of nitroglycerin or other short-acting nitrates.
Prevention of variant (Prinzmetal's) angina through coronary artery vasodilation.
Use in combination with beta-blockers or calcium channel blockers for enhanced antianginal effect.
Symptomatic relief in patients with esophageal spasm associated with angina-like symptoms.
Management of stable angina refractory to other antianginal therapies.
Potential off-label use for pulmonary hypertension in specific clinical settings.
Prevention of angina in perioperative cardiac surgery patients as part of multi-drug regimens.
Improvement of exercise tolerance in patients with stable coronary artery disease.
Reduction of anginal burden improving quality of life and functional status.
Part of guideline-recommended therapy for secondary prevention in coronary artery disease.
Use in patients with contraindications to beta-blockers who require antianginal treatment.

Side Or Adverse Effects

Severe headache, particularly at treatment initiation due to vasodilation of cerebral vessels.
Flushing, warmth, or redness of the skin due to systemic vasodilation.
Dizziness or light-headedness, especially upon standing (orthostatic hypotension).
Hypotension leading to potential syncope or falls in predisposed individuals.
Tachycardia or palpitations as a reflex sympathetic response to vasodilation.
Nausea and gastrointestinal discomfort in some patients.
Potential exacerbation of angina symptoms with sudden discontinuation of therapy.
Allergic reactions ranging from rash and urticaria to severe anaphylaxis (rare).
Tolerance development with continuous exposure leading to decreased efficacy.
Rare occurrences of methemoglobinemia with high doses or prolonged use.
Facial flushing and warmth causing patient discomfort and potential nonadherence.
Hypersensitivity reactions including swelling of face, lips, or extremities.
Increase in intraocular pressure in susceptible individuals.
Dyspepsia or gastric irritation reported infrequently.
Fatigue and weakness secondary to systemic hypotensive effects.

Precautions

Avoid use with phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil) due to risk of severe hypotension.
Caution in patients with hypotension or volume depletion; monitor blood pressure closely.
Avoid abrupt discontinuation to prevent rebound angina or myocardial ischemia.
Use cautiously in patients with congestive heart failure, monitoring for hypotension and renal function.
Monitor renal function since impairment may alter drug clearance and increase side effects.
Exercise caution in elderly patients who may have increased sensitivity to vasodilators.
Avoid concurrent use with other nitrates or agents causing vasodilation unless prescribed by a physician.
Patients should be advised to rise slowly from seated or lying positions to prevent falls.
Use with caution during pregnancy; limited data available; assess risk-benefit ratio.
Breastfeeding mothers should consult healthcare providers due to uncertain excretion into milk.
Avoid alcohol consumption as it may exacerbate hypotensive and sedative side effects.
Careful monitoring during initiation for development of severe headaches or hypotension.
Advise patients to report any signs of angina worsening or allergic reactions promptly.
Regular review of concomitant medications to exclude harmful drug interactions.
Educate patients about the importance of adherence to dosing schedule to maintain efficacy and reduce tolerance.

Warnings

Do not use concomitantly with erectile dysfunction medications due to potentially fatal hypotension.
Seek immediate medical attention if symptoms of myocardial infarction occur despite treatment.
Never abruptly discontinue isosorbide mononitrate therapy to avoid severe angina exacerbation.
Severe headaches can occur initially, but do not stop medication without consulting healthcare provider.
Risk of orthostatic hypotension and syncope, especially in those with cardiovascular comorbidities.
Excessive dosing or overdose can cause life-threatening hypotension requiring emergency intervention.
Use caution in patients with cerebrovascular disease due to potential for blood pressure fluctuations.
May impair cognitive or motor skills; patients should avoid driving or operating machinery until effects known.
Store medication securely out of reach of children to prevent accidental overdose fatalities.
Report any unusual bleeding, swelling, or signs of allergic reaction immediately.
In patients with hypertrophic cardiomyopathy, vasodilators may worsen outflow obstruction.
Use is contraindicated in patients with early signs of myocardial infarction or unstable angina.
Closely monitor blood pressure in patients receiving concomitant antihypertensive therapy.
Concurrent use with other nitrates or vasodilators requires careful clinical supervision.
Do not use in patients with known hypersensitivity to isosorbide mononitrate or related nitrates.

Contraindication

Hypersensitivity to isosorbide mononitrate, isosorbide dinitrate, nitroglycerin, or other nitrate compounds.
Concomitant use with phosphodiesterase-5 inhibitors such as sildenafil, tadalafil, vardenafil.
Marked hypotension or severe anemia where vasodilation may worsen hemodynamics.
Early signs of acute myocardial infarction (chest pain with spreading, nausea, sweating).
Increased intracranial pressure or cerebral hemorrhage due to risk of exacerbating edema.
Known hypersensitivity or allergic reactions to components of the formulation.
Use in patients with severe aortic stenosis or constrictive pericarditis without specialist supervision.
Shock or states of reduced systemic perfusion without appropriate cardiovascular support.
Concomitant use with riociguat (Adempas) due to risk of hypotension.
Use with caution or avoid in patients with hypertrophic obstructive cardiomyopathy.
Patients with severe hepatic impairment where pharmacokinetic data are limited.
Contraindicated during acute circulatory failure or decompensated states.
Use in patients with severe volume depletion or dehydration is contraindicated without correction.
Known intolerance to any excipients in specific extended-release tablet formulations.
Not indicated for acute relief of an angina attack, thus contraindicated for monotherapy in acute angina episodes.

Drug Interactions

Severe hypotension when combined with phosphodiesterase-5 inhibitors (Viagra, Cialis, Levitra, Stendra, Staxyn).
Additive blood pressure lowering effects with other antihypertensives including calcium channel blockers and beta-blockers.
Enhanced vasodilatory effects and risk of hypotension with concomitant use of diuretics (water pills).
Potential interactions with nitrates such as nitroglycerin leading to nitrate overdose and hypotension.
Riociguat coadministration increases hypotension risk due to additive effects on the nitric oxide pathway.
Alcohol increases risk of dizziness, syncope, and orthostatic hypotension when combined with isosorbide mononitrate.
Careful monitoring required if used with other vasodilators including alpha-blockers or hydralazine.
Limited interaction with hepatic enzyme inducers or inhibitors due to minimal metabolism; interactions uncommon.
Drugs affecting renal function may alter isosorbide mononitrate clearance and require dose adjustments.
Use with caution when combined with antihypertensive agents such as ACE inhibitors or ARBs for additive hypotensive effects.
Additive headache and flushing effects when used with other vasodilators.
Potential interference with digitalis effects due to altered hemodynamics.
No significant interaction with antiplatelet or anticoagulant agents, but monitor for bleeding risks.
Medications that impair CNS function may exacerbate dizziness and light-headedness induced by isosorbide mononitrate.
Concurrent use with other nitrate-containing compounds should be avoided unless under strict supervision.

Preparations Of The Drug

Isosorbide mononitrate extended-release tablets: 10 mg, 20 mg, 30 mg, 40 mg strengths designed for once or twice daily dosing.
Immediate-release tablets typically available as 20 mg or 30 mg formulations for multiple daily dosing.
Oral tablets prepared for administration with instructions to swallow whole, not to crush or chew to preserve release characteristics.
Various brand formulations including Imdur, Monoket, and ISMO, with FDA-approved labeling for angina prophylaxis.
Available in packaging with child-resistant containers for safety due to hazard of overdose.
Formulations may include film-coated tablets to improve patient compliance and reduce gastrointestinal irritation.
Stable at room temperature when stored away from moisture, heat, and light per labeling instructions.
Commercially available generics offer cost-effective alternatives with equivalent pharmacokinetic and pharmacodynamic profiles.
Manufactured under quality-controlled conditions adhering to cGMP standards ensuring batch-to-batch consistency.
Formulations intended exclusively for oral administration; no approved parenteral forms currently available.
Scored tablets available in some brands to facilitate dose adjustments when prescribed.
Supply available in various pack sizes to accommodate different therapy durations from initiation to maintenance.